TWD 16.9
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 910.11 Million TWD | -8.93% |
2022 | 999.4 Million TWD | -26.51% |
2021 | 1.35 Billion TWD | 21.93% |
2020 | 1.11 Billion TWD | 40.98% |
2019 | 791.06 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 1.03 Billion TWD | 13.2% |
2024 Q2 | 1.03 Billion TWD | 0.0% |
2023 Q3 | 910.11 Million TWD | -16.21% |
2023 FY | 910.11 Million TWD | -8.93% |
2023 Q1 | 1.08 Billion TWD | 8.68% |
2023 Q2 | 1.08 Billion TWD | 0.0% |
2023 Q4 | 910.11 Million TWD | 0.0% |
2022 Q4 | 999.4 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -222.122% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | -54.26% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 72.984% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 74.912% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 86.313% |
Center Laboratories, Inc. | 6.78 Billion TWD | 86.588% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -465.107% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | -2.01% |
InnoPharmax Inc. | 48.64 Million TWD | -1770.78% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | -183.531% |
Excelsior Biopharma Inc. | 472.87 Million TWD | -92.465% |
DV Biomed Co., Ltd. | 765.87 Million TWD | -18.834% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | -47.523% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -224.022% |
UniPharma Co., Ltd. | 37.4 Million TWD | -2333.4% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 10.363% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -1096.12% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | -143.428% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -1730.446% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -736.873% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -581.092% |